fluorouracil has been researched along with Nervous System Disorders in 51 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)." | 9.17 | Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 9.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 9.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients." | 9.08 | Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. ( Hande, KR; Johnson, DH; Paul, D, 1997) |
| "Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer." | 7.74 | [Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008) |
| "The purpose of this study is to determine the characteristic clinical features, radiologic findings, and precipitating and prognostic factors in the patients with breast cancer and with 5-Fluorouracil (5-FU)-induced leukoencephalopathy." | 7.71 | 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. ( Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 7.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 6.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "Patients with metastatic colorectal cancer (MCC) usually receive FOLFOX-4, or other oxaliplatin (L-HOP)-based regimens, until the occurrence of progressive disease, with an increase in the incidence of neurotoxicity which is correlated to the cumulative dose of L-HOP." | 6.72 | FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. ( Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G, 2006) |
| "The aim of this multicenter, open-label, randomized phase II trial was to evaluate the efficacy of a dose-dense capecitabine and oxaliplatin (XELOX) regimen in patients with metastatic colorectal cancer (mCRC) for whom reintroduction of oxaliplatin had been planned as a third- or later-line regimen." | 5.22 | Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). ( Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y, 2016) |
| "Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)." | 5.17 | Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 5.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 5.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients." | 5.08 | Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. ( Hande, KR; Johnson, DH; Paul, D, 1997) |
| "In an attempt to improve the primary treatment of malignant gliomas we used a concomitant 6-week course of chemoradiotherapy with 5 fluorouracil (5 FU) and hydroxyurea (HU) in 24 adults with anaplastic astrocytoma (AA) (7 cases) or glioblastomas (GLB) (17 cases)." | 5.07 | Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. ( Armand, JP; Cioloca, C; Constans, JP; Cvitkovic, FB; Haie-Meder, C; Maugis, N; Papadimitrakopoulou, V, 1993) |
| "Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer." | 3.74 | [Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008) |
| "The purpose of this study is to determine the characteristic clinical features, radiologic findings, and precipitating and prognostic factors in the patients with breast cancer and with 5-Fluorouracil (5-FU)-induced leukoencephalopathy." | 3.71 | 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. ( Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 3.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population." | 2.87 | Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. ( Andre, T; Boukovinas, I; Grothey, A; Iveson, T; Kerr, R; Labianca, R; Meyerhardt, JA; Meyers, JP; Niedzwiecki, D; Paul, J; Renfro, LA; Sargent, DJ; Saunders, M; Shi, Q; Shields, AF; Sobrero, AF; Souglakos, J; Taieb, J; Torri, V; Vernerey, D; Watanabe, T; Yamanaka, T; Yoshino, T, 2018) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 2.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| " Follow-up for potential delayed adverse effects and efficacy is ongoing." | 2.74 | Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. ( Allegra, CJ; Atkins, JN; Azar, CA; Chu, L; Colangelo, LH; Fehrenbacher, L; Goldberg, RM; Lopa, SH; O'Connell, MJ; O'Reilly, S; Petrelli, NJ; Seay, TE; Sharif, S; Wolmark, N; Yothers, G, 2009) |
| "Patients with metastatic colorectal cancer (MCC) usually receive FOLFOX-4, or other oxaliplatin (L-HOP)-based regimens, until the occurrence of progressive disease, with an increase in the incidence of neurotoxicity which is correlated to the cumulative dose of L-HOP." | 2.72 | FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. ( Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G, 2006) |
| "courses in 15 patients with cancer of different origins." | 2.68 | Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. ( Gabizon, AA; Gorodetsky, R; Mou, X; Vexler, AM, 1995) |
| "Radiation complications included pneumonitis three of 30 (10%) and esophagitis (27%)." | 2.66 | Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer. ( Chaffey, J; Lokich, J; Neptune, W, 1989) |
| "Pretreatment with allopurinol did not reduce the toxicity of 5-FU administered as an intravenous bolus." | 2.65 | Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. ( Howell, SB; Pfeifle, CE; Wung, WE, 1983) |
| "5-Fluorouracil (5-FU) is an analogue of pyrimidine nucleosides that is widely used in the treatment of head and neck, breast, ovarian, and colon cancer." | 2.40 | Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. ( Pater, A; Shehata, N; Tang, SC, 1999) |
| "These neurologic disorders can be either metastatic to the brain, spinal cord, leptomeninges, or peripheral nerves or nonmetastatic including infections, vascular problems, metabolic abnormalities, side effects of therapy, or paraneoplastic syndromes." | 2.37 | Neurologic complications of systemic cancer. ( Patchell, RA; Posner, JB, 1985) |
| " 5-Fluorouracil at high dosage may cause cerebellar ataxia, but may also do so at low dosage when combined with thymidine infusions." | 2.37 | Neurological complications of antineoplastic therapy. ( Shapiro, WR; Young, DF, 1984) |
| "Fluorouracil (5-FU) is a commonly used chemotherapeutic agent in many cancers." | 1.62 | 5-Fluorouracil associated neurovascular toxicities. ( Dumas, B; Horta, L; Ozer, M; Sadrzadeh, H, 2021) |
| "Alopecia was observed in 60% of patients." | 1.62 | Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. ( Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A, 2021) |
| "Our analysis confirms that women with colon cancer receiving adjuvant fluoropyrimidine-based chemotherapy are at increased risk of toxicity." | 1.62 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021) |
| " Adverse events occurred in 88." | 1.56 | Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms. ( Arsenic, R; Dal Buono, A; Denecke, T; Jann, H; Merola, E; Pape, UF; Pavel, ME; Wiedenmann, B, 2020) |
| " Toxicity over four cycles was graded according to NCI Common Toxicity Criteria V2 or V3 (Common Terminology Criteria for Adverse Events, National Cancer Institute, Bethesda, MD)." | 1.43 | Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. ( Ali, R; Assenat, E; Baracos, VE; Bianchi, L; Mollevi, C; Roberts, S; Sawyer, MB; Senesse, P, 2016) |
| " This treatment should be considered regardless of patients' age alone, but consideration should be given to the capacity of patients to tolerate adverse events." | 1.40 | Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. ( Bedenne, L; Bouvier, AM; Faivre, J; Hamza, S; Lepage, C; Rollot, F, 2014) |
| "Uracil plus tegafur was shown to be less toxic than the drug alone in all the species, and uracil was found to decrease the toxicity of tegafur." | 1.27 | Effect of coadministration of uracil on the toxicity of tegafur. ( Haruno, A; Kunimune, Y; Morita, K; Unemi, N; Yamamoto, J; Yamashita, K; Yoshimura, Y, 1984) |
| "Among 26 colorectal cancer patients assessable for response there was a 15." | 1.26 | Allopurinol modulation of fluorouracil toxicity. ( Fox, RM; Piper, AA; Sampson, D; Tattersall, MH; Woods, RL, 1981) |
| " Although the neurotoxic effects produced by different cytostatics present a different appearance and are partly of only sporadic or slight clinical importance, there is hardly a cytostatic which does not exercise a side effect on the nervous system." | 1.26 | [Neurotoxic side effects of cytostatic therapy (author's transl)]. ( Maurach, R; Strian, F, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (33.33) | 18.7374 |
| 1990's | 8 (15.69) | 18.2507 |
| 2000's | 11 (21.57) | 29.6817 |
| 2010's | 9 (17.65) | 24.3611 |
| 2020's | 6 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Iimura, Y | 1 |
| Kurokawa, T | 1 |
| Nojima, M | 1 |
| Kanemoto, Y | 1 |
| Yazawa, K | 1 |
| Tsurita, G | 1 |
| Kuroda, S | 1 |
| Ron, DA | 1 |
| Vera, R | 1 |
| Labandeira, CM | 1 |
| Manrique, MCA | 1 |
| Núñez, MÁ | 1 |
| Cid, NG | 1 |
| Mata, JG | 1 |
| Montes, AF | 1 |
| Merola, E | 1 |
| Dal Buono, A | 1 |
| Denecke, T | 1 |
| Arsenic, R | 1 |
| Pape, UF | 1 |
| Jann, H | 1 |
| Wiedenmann, B | 1 |
| Pavel, ME | 1 |
| Wagner, AD | 1 |
| Grothey, A | 2 |
| Andre, T | 4 |
| Dixon, JG | 1 |
| Wolmark, N | 2 |
| Haller, DG | 1 |
| Allegra, CJ | 2 |
| de Gramont, A | 3 |
| VanCutsem, E | 1 |
| Alberts, SR | 1 |
| George, TJ | 1 |
| O'Connell, MJ | 2 |
| Twelves, C | 1 |
| Taieb, J | 2 |
| Saltz, LB | 1 |
| Blanke, CD | 1 |
| Francini, E | 2 |
| Kerr, R | 2 |
| Yothers, G | 2 |
| Seitz, JF | 1 |
| Marsoni, S | 1 |
| Goldberg, RM | 2 |
| Shi, Q | 2 |
| Ben Nasr, S | 1 |
| Zribi, A | 1 |
| Ben Hassen, M | 1 |
| Doghri, Y | 1 |
| Ben Abdallah, I | 1 |
| Trigui, E | 1 |
| Fendri, S | 1 |
| Ayari, J | 1 |
| Balti, M | 1 |
| Haddaoui, A | 1 |
| Ozer, M | 1 |
| Dumas, B | 1 |
| Horta, L | 1 |
| Sadrzadeh, H | 1 |
| Sobrero, AF | 1 |
| Shields, AF | 1 |
| Yoshino, T | 1 |
| Paul, J | 1 |
| Souglakos, J | 1 |
| Labianca, R | 1 |
| Meyerhardt, JA | 1 |
| Vernerey, D | 1 |
| Yamanaka, T | 1 |
| Boukovinas, I | 1 |
| Meyers, JP | 1 |
| Renfro, LA | 1 |
| Niedzwiecki, D | 1 |
| Watanabe, T | 1 |
| Torri, V | 1 |
| Saunders, M | 1 |
| Sargent, DJ | 1 |
| Iveson, T | 1 |
| Cohen, PR | 1 |
| Tonyali, O | 1 |
| Benekli, M | 1 |
| Berk, V | 1 |
| Coskun, U | 1 |
| Ozkan, M | 1 |
| Yildiz, R | 1 |
| Ucgul, E | 1 |
| Sevinc, A | 1 |
| Uncu, D | 1 |
| Demirci, U | 1 |
| Buyukberber, S | 1 |
| Hamza, S | 1 |
| Bouvier, AM | 1 |
| Rollot, F | 1 |
| Lepage, C | 1 |
| Faivre, J | 1 |
| Bedenne, L | 1 |
| Ko, AH | 1 |
| LoConte, N | 1 |
| Tempero, MA | 1 |
| Walker, EJ | 1 |
| Kate Kelley, R | 1 |
| Lewis, S | 1 |
| Chang, WC | 1 |
| Kantoff, E | 1 |
| Vannier, MW | 1 |
| Catenacci, DV | 1 |
| Venook, AP | 1 |
| Kindler, HL | 1 |
| Matsuda, C | 1 |
| Honda, M | 1 |
| Tanaka, C | 1 |
| Fukunaga, M | 1 |
| Ishibashi, K | 1 |
| Munemoto, Y | 1 |
| Hata, T | 1 |
| Bando, H | 1 |
| Oshiro, M | 1 |
| Kobayashi, M | 1 |
| Tokunaga, Y | 1 |
| Fujii, A | 1 |
| Nagata, N | 1 |
| Oba, K | 1 |
| Mishima, H | 1 |
| Ali, R | 1 |
| Baracos, VE | 1 |
| Sawyer, MB | 1 |
| Bianchi, L | 1 |
| Roberts, S | 1 |
| Assenat, E | 1 |
| Mollevi, C | 1 |
| Senesse, P | 1 |
| Fujii, C | 1 |
| Anami, S | 1 |
| Fujino, M | 1 |
| Yasui, Y | 1 |
| Fujita, M | 1 |
| Inoue, M | 1 |
| Nakayama, T | 1 |
| Kamigaki, S | 1 |
| Tatsuta, M | 1 |
| Furukawa, H | 1 |
| Sharif, S | 1 |
| Colangelo, LH | 1 |
| Lopa, SH | 1 |
| Petrelli, NJ | 1 |
| Atkins, JN | 2 |
| Seay, TE | 1 |
| Fehrenbacher, L | 1 |
| O'Reilly, S | 1 |
| Chu, L | 1 |
| Azar, CA | 1 |
| Kanai, M | 1 |
| Yoshioka, A | 1 |
| Tanaka, S | 1 |
| Nagayama, S | 1 |
| Matsumoto, S | 1 |
| Nishimura, T | 1 |
| Niimi, M | 1 |
| Teramukai, S | 1 |
| Takahashi, R | 1 |
| Mori, Y | 1 |
| Kitano, T | 1 |
| Ishiguro, H | 1 |
| Yanagihara, K | 1 |
| Chiba, T | 1 |
| Fukushima, M | 1 |
| Matsuda, F | 1 |
| Karachaliou, N | 1 |
| Ziras, N | 1 |
| Syrigos, K | 1 |
| Tryfonidis, K | 1 |
| Papadimitraki, E | 1 |
| Kontopodis, E | 1 |
| Bozionelou, V | 1 |
| Kalykaki, A | 1 |
| Georgoulias, V | 1 |
| Mavroudis, D | 1 |
| Sucker, C | 1 |
| Lambers, C | 1 |
| Stockschläder, M | 1 |
| Dölken, G | 1 |
| Louvet, C | 2 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 2 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| Gamelin, E | 1 |
| Chang, HM | 1 |
| Kim, TW | 1 |
| Ryu, BY | 1 |
| Choi, SJ | 1 |
| Park, YH | 1 |
| Lee, JS | 1 |
| Kim, WK | 1 |
| Kang, YK | 1 |
| Petrioli, R | 1 |
| Paolelli, L | 1 |
| Marsili, S | 1 |
| Civitelli, S | 1 |
| Cioppa, T | 1 |
| Roviello, F | 1 |
| Nettuno, R | 1 |
| Intrivici, C | 1 |
| Tanzini, G | 1 |
| Lorenzi, M | 1 |
| Francini, G | 1 |
| Wang, WS | 1 |
| Lin, JK | 1 |
| Lin, TC | 1 |
| Chen, WS | 1 |
| Jiang, JK | 1 |
| Wang, HS | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Yen, CC | 1 |
| Chen, PM | 1 |
| Ota, K | 1 |
| Kishida, S | 1 |
| Singer, Z | 1 |
| Kozaczka, A | 1 |
| Wilk, J | 1 |
| Janas, J | 1 |
| Howell, SB | 1 |
| Pfeifle, CE | 1 |
| Wung, WE | 1 |
| Shapiro, WR | 1 |
| Young, DF | 1 |
| Yamamoto, J | 1 |
| Haruno, A | 1 |
| Yoshimura, Y | 1 |
| Unemi, N | 1 |
| Kunimune, Y | 1 |
| Yamashita, K | 1 |
| Morita, K | 1 |
| Fox, RM | 1 |
| Woods, RL | 1 |
| Tattersall, MH | 1 |
| Piper, AA | 1 |
| Sampson, D | 1 |
| Kish, JA | 1 |
| Weaver, A | 1 |
| Jacobs, J | 1 |
| Cummings, G | 1 |
| Al-Sarraf, M | 1 |
| Strian, F | 2 |
| Maurach, R | 2 |
| Vexler, AM | 1 |
| Mou, X | 1 |
| Gabizon, AA | 1 |
| Gorodetsky, R | 1 |
| Cvitkovic, FB | 1 |
| Haie-Meder, C | 1 |
| Papadimitrakopoulou, V | 1 |
| Armand, JP | 1 |
| Cioloca, C | 1 |
| Maugis, N | 1 |
| Constans, JP | 1 |
| Johnson, DH | 1 |
| Paul, D | 1 |
| Hande, KR | 1 |
| Shehata, N | 1 |
| Pater, A | 1 |
| Tang, SC | 1 |
| Fabian, A | 1 |
| Maindrault-Goebel, F | 1 |
| Carola, E | 1 |
| Gilles, V | 1 |
| Lotz, JP | 1 |
| Tournigand, C | 1 |
| Molitor, JL | 1 |
| Artru, P | 1 |
| Izrael, V | 1 |
| Krulik, M | 1 |
| Choi, SM | 1 |
| Lee, SH | 1 |
| Yang, YS | 1 |
| Kim, BC | 1 |
| Kim, MK | 1 |
| Cho, KH | 1 |
| Osterlund, P | 1 |
| Elomaa, I | 1 |
| Virkkunen, P | 1 |
| Joensuu, H | 1 |
| Harvey, HJ | 1 |
| MacEwen, EG | 1 |
| Hayes, AA | 1 |
| Henness, AM | 1 |
| Theilen, GH | 1 |
| Madewell, BR | 1 |
| Crow, SE | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Gottlieb, JA | 1 |
| Freireich, EJ | 1 |
| Kuzuhara, S | 1 |
| van der Hoop, RG | 1 |
| van der Burg, ME | 1 |
| ten Bokkel Huinink, WW | 1 |
| van Houwelingen, C | 1 |
| Neijt, JP | 1 |
| Moore, DH | 1 |
| Fowler, WC | 1 |
| Crumpler, LS | 1 |
| Vukelja, SJ | 1 |
| Lombardo, FA | 1 |
| James, WD | 1 |
| Weiss, RB | 1 |
| Lokich, J | 1 |
| Chaffey, J | 1 |
| Neptune, W | 1 |
| Patchell, RA | 1 |
| Posner, JB | 1 |
| Weiss, HD | 1 |
| Walker, MD | 1 |
| Wiernik, PH | 1 |
| Ahmann, DL | 1 |
| Bisel, HF | 1 |
| Hahn, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Follow-up and Registration Study of Anlotinib Combined With Adjuvant Chemotherapy in the Treatment of Locally Advanced Gastrointestinal Tumors[NCT05742620] | 100 participants (Anticipated) | Interventional | 2023-06-20 | Not yet recruiting | |||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| Coala-T-CBD Study: A Study of the Effect of Hemp-CBD on the Severity and Duration of Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy for Non-Metastatic Breast, Uterine, Pancreatic, and Colorectal Cancer and All Sta[NCT04398446] | Phase 2 | 56 participants (Actual) | Interventional | 2020-05-27 | Active, not recruiting | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for fluorouracil and Nervous System Disorders
| Article | Year |
|---|---|
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Ca | 2020 |
Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil.
Topics: Administration, Cutaneous; Aged; Angioedema; Antimetabolites, Antineoplastic; Cheilitis; Fluorouraci | 2018 |
[Neurotoxicity of 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Cerebellar Ataxia; Fluorouracil; Humans; Leukoencephalopathy, Progr | 2002 |
[Drug-induced leukoencephalopathy].
Topics: Antineoplastic Agents; Brain Edema; Cisplatin; Cytarabine; Fluorouracil; Humans; Hypertensive Enceph | 2007 |
Neurological complications of antineoplastic therapy.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemother | 1984 |
[Cytostatic therapy: neurologic and psychiatric syndromes].
Topics: Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Doxoru | 1980 |
Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Topics: Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Male; Middle Aged; Nerv | 1999 |
[Neurological disorders induced by antineoplastic drugs].
Topics: Animals; Antineoplastic Agents; Cell Division; Cisplatin; Fluorouracil; Humans; Methotrexate; Nervou | 1992 |
Neurologic complications of systemic cancer.
Topics: Arachnoid; Bacterial Infections; Brain; Brain Neoplasms; Cerebrovascular Disorders; Cisplatin; Disse | 1985 |
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Brain; Brain Diseases; Fluorouracil; Humans; Leukemia; | 1974 |
17 trials available for fluorouracil and Nervous System Disorders
| Article | Year |
|---|---|
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2013 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; | 2016 |
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2012 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carbo | 2005 |
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2006 |
Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Dis | 2007 |
Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection.
Topics: Allopurinol; Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Humans; Inflammation; Leukocyt | 1983 |
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1995 |
Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1993 |
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatigue; Female; Fluo | 1997 |
[Evaluation of nervous system disorders during the course of gastric carcinoma on the basis of clinical electrophysiologic analysis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Ad | 1999 |
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2000 |
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici | 1990 |
Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Esophagit | 1989 |
24 other studies available for fluorouracil and Nervous System Disorders
| Article | Year |
|---|---|
Potential thiamine deficiency and neurological symptoms in patients receiving chemotherapy for gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouracil; Folic Acid; G | 2020 |
Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2020 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit | 2021 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases | 2021 |
5-Fluorouracil associated neurovascular toxicities.
Topics: Adult; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Male; Middle Aged; Nervous Sys | 2021 |
Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neopla | 2014 |
Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Body Surfac | 2016 |
[Management of hand-foot syndrome in patient treated with capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil | 2008 |
Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2010 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
[Non-hematologic adverse effects of cytostatic drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Diarrhea; Drug Eruptions; Female; | 1984 |
Effect of coadministration of uracil on the toxicity of tegafur.
Topics: Animals; beta-Alanine; Cats; Dogs; Female; Fluorouracil; Heart Diseases; Lethal Dose 50; Male; Mice; | 1984 |
Allopurinol modulation of fluorouracil toxicity.
Topics: Allopurinol; Drug Eruptions; Drug Therapy, Combination; Fluorouracil; Hematologic Diseases; Humans; | 1981 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
[Neurotoxic side effects of cytostatic therapy (author's transl)].
Topics: Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Doxoru | 1981 |
5-fluorouracil-induced leukoencephalopathy in patients with breast cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Brain; Breast Neop | 2001 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2001 |
Neurotoxicosis associated with use of 5-fluorouracil in five dogs and one cat.
Topics: Animals; Ataxia; Blindness; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Fluorouracil; Male; Nerv | 1977 |
Neurotoxicosis associated with use of 5-florouracil.
Topics: Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Fluorouracil; Nervous System Diseases | 1977 |
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise | 1976 |
5-Fluorouracil neurotoxicity.
Topics: Adult; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; Nervous System Diseases; | 1990 |
Pyridoxine for the palmar-plantar erythrodysesthesia syndrome.
Topics: Dermatitis, Exfoliative; Fluorouracil; Hand Dermatoses; Humans; Male; Middle Aged; Nervous System Di | 1989 |
Fluorouracil and the palmar-plantar erythrodysesthesia syndrome.
Topics: Dermatitis, Exfoliative; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged | 1985 |
A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.
Topics: Alopecia; Blood Platelets; Breast Neoplasms; Castration; Cyclohexanes; Cyclophosphamide; Drug Evalua | 1974 |